# Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

> **NCT00217581** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00217581
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2012-11
- **Final completion:** 2013-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217581, "Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00217581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*